Volume : 12, Issue : 01, January – 2025
Title:
NANOTECHNOLOGY IN DRUG DELIVERY SYSTEMS
Authors :
Tejal P. Bute*, Kalyani N. Sadafale , Aditya A. Unhale, Dr. Swati P. Deshmukh
Abstract :
The developed field of nanotechnology will drastically alter the course of human history. Growing nanotechnology is expected to usher in “the Next Industrial Revolution,” as some legislators and IT developers have even gone so far as to refer to it. Nonetheless, since nanotechnology is still in its infancy, opinions about its definition and fundamentals are far from universal. There are others who argue that nanotechnology is a distinct field of study and that it falls under the umbrella of general purpose technology (GPT). By delivering the medication to the site of action, controlled drug delivery systems (DDS) help reduce the drug’s impact on important tissues and unwanted side effects. Lower drug dosages are necessary since DDS also prevents the medication from degrading or clearing too quickly and increases drug concentration in target tissues. Poor physiochemical characteristics in many promising novel compounds limit their solubility and biodistribution, preventing the medicine from interacting with the site of action Low solubility at physiological pH and poor oral absorption of proteins and peptides ,One barrier to drug development is the quick disposal of drugs and poor cellular absorption. Prospective drugs need to demonstrate that they can go to the site of action and produce an impact. Drug delivery research develops excipients, transporters, and solubilizers that deliver medications to their intended sites of action [1].
Keywords: Drug delivery, Gold nanoparticle, Magnetic nanoparticle, Ceremic Nanoparticle , Niosomes, Liposomes, Dendrimer, Nanoemulsion , Nanosuspension, Nanoparticle based on Solid lipid, Silica nanoparticle, Nanocrystal.
Cite This Article:
Please cite this article in press Tejal P. Bute et al Nanotechnology In Drug Delivery Systems.,Indo Am. J. P. Sci, 2025; 12 (01).
Number of Downloads : 10
References:
1. Williams D. Nanotechnology: a new look. Med Device Technol 2004; 15:9 – 10.
2. Freitas RA.What is nanomedicine. Stud Health Technol Inform 2002; 80: 45-59. Anderson A, Allan S, Petersen A, Wilkinson C.The framing of nanotechnologies in the British newspaper press. Science Communication 2005;27:200–220.
3. Joshi HM, Bhumkar DR, Joshi K, Pokharkar V, Sastry M. Gold nanoparticles as carriers for efficient transmucosal insulin delivery. Langmuir 2006; 22: 300–305.
4. Charles S W and Popplewell J. Properties and applications of magnetic liquids. J Am Chem Soc 1993; 19:8706-8715.
5. Yamashita D, Machigashira M, Miyamoto M, Takeuchi H, Noguchi K, Izumi Y. Effect of surface roughness on initial responses of osteoblast-like cells on two types of zirconia. Dental Materials Journal 2009; 28:461-470.
6. A. Chonn, R.P. Cullis, Recent advances in liposomal drug-delivery systems, Current Opinion in Biotechnology 6 (1995) 698-708. 35..A.D. Tomalia, A.L. Reyna, S. Svenson, Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging, Biochemical Society Transactions 35 (2007) part 1.
7. D. Bharali, M. Khalil, M. Gurbuz, M.T. Simone, A.S. Mousa, Nanoparticles and A cancer therapy: a concise review with emphasis on dendrimers, International Journal of Nanomedicine 4 (2009) 1-7.
8. U. Boas, J.B. Christensen, P.M.H. Heegaard, Dendrimers in
9. Medicine and Biotechnology, The Royal Society of Chemistry, Cambridge (2006) 62-124.
10. Sayes CM, Liang F, Hudson JL, Mendez J, Guo W, Beach JM, Moore VC et al.: Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicol Lett, 2006, 161, 135–142.
11. Üner M, Yener G: Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine, 2007, 2, 289–300.
12. Hocine O, Gary-Bobo M, Brevet D, Maynadier M, Fontanel S, Raehm L, Richeter S et al.: Silicalites and mesoporous silica nanoparticles for photodynamic therapy. Int J Pharm, 2010, 402, 221–230.
13. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V: Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release, 2006,116, 1–27.
14. Tadros T, Izquierdo P, Esquena J, Solans C. Formation and stability of nanoemulsions. Adv Colloid Interface Sci 2004; 109: 303–318.
15. Emeje M, Africa J, Lucy, Isimi Y, Kunle O, Ofoefule S. Eudraginated – polymer blends: a potential oral controlled drug delivery system for theophylline. Acta Pharmaceutical 2012;
16. 62: 71 – 82.
17. 15.Emerich DF.Nanomedicine prospective therapeutic and diagnostic Applications. Expert Opin Biol Ther 2005; 5:1 – 5.
18. Zhang L, Gu FX, Chan JM, Wang AZ, Langer R.S and Farokhzad OC (2008) Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761-
19. 769.
20. 17.Wagner V, Dullaart A, Bock A-K, Zweck A. The emerging nanomedicine landscape. Nature Biotechnology 2006; 24:1211-1217.